Global Compound Bone Peptide for Injection 麻豆原创 Research Report 2023

Publication ID:

PB504235488

Publication Date:

May 15, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Compound bone peptide preparation, wherein, the compound bone peptide preparation is produced by mixing bone peptide extracting solution and scorpion extracting solution, performing acid treatment and alkali treatment to the mixed solution in sequence, regulating the pH value of the mixed solution after the alkali treatment is performed to be neutral, and ensuring the mixed solution with neutral pH value to contact with active carbon. The compound bone peptide preparation of the invention can be produced to be small capacity injection and freeze-dried powder injection. Compared with the prior method that the bone peptide extracting solution and the scorpion extracting solution are respectively and singly treated and then mixed, the compound bone peptide preparation provided by the invention is produced through acid precipitation, alkali precipitation and active carbon adsorption to the mixed solution of the bone peptide extracting solution and the scorpion extracting solution, can effectively remove impurity generated through the interaction because of the mixing of the bone peptide extracting solution and the scorpion extracting solution, and thereby obviously improving the clarity and reducing the injection irritability of the compound bone peptide preparation (namely improving the injection compliance).
Highlights
The global Compound Bone Peptide for Injection market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Compound Bone Peptide for Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Compound Bone Peptide for Injection is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Compound Bone Peptide for Injection include Jiangshi Pharma, Zhitong Biopharma and Xinbai Pharmaceutical, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Compound Bone Peptide for Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Compound Bone Peptide for Injection.
The Compound Bone Peptide for Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Compound Bone Peptide for Injection market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Compound Bone Peptide for Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Jiangshi Pharma
Zhitong Biopharma
Xinbai Pharmaceutical
Segment by Type
Intramuscular Injection
Intravenous Drip
Segment by Application
Rheumatism
Rheumatoid Arthritis
Osteoporosis
Cervical spondylosis
Post-fracture healing
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Compound Bone Peptide for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Compound Bone Peptide for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Compound Bone Peptide for Injection 麻豆原创 Overview
1.1 Product Overview and Scope of Compound Bone Peptide for Injection
1.2 Compound Bone Peptide for Injection Segment by Type
1.2.1 Global Compound Bone Peptide for Injection 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Intramuscular Injection
1.2.3 Intravenous Drip
1.3 Compound Bone Peptide for Injection Segment by Application
1.3.1 Global Compound Bone Peptide for Injection 麻豆原创 Value by Application: (2023-2029)
1.3.2 Rheumatism
1.3.3 Rheumatoid Arthritis
1.3.4 Osteoporosis
1.3.5 Cervical spondylosis
1.3.6 Post-fracture healing
1.3.7 Others
1.4 Global Compound Bone Peptide for Injection 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Compound Bone Peptide for Injection Revenue 2018-2029
1.4.2 Global Compound Bone Peptide for Injection Sales 2018-2029
1.4.3 Global Compound Bone Peptide for Injection 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Compound Bone Peptide for Injection 麻豆原创 Competition by Manufacturers
2.1 Global Compound Bone Peptide for Injection Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Compound Bone Peptide for Injection Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Compound Bone Peptide for Injection Average Price by Manufacturers (2018-2023)
2.4 Global Compound Bone Peptide for Injection Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Compound Bone Peptide for Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Compound Bone Peptide for Injection, Product Type & Application
2.7 Compound Bone Peptide for Injection 麻豆原创 Competitive Situation and Trends
2.7.1 Compound Bone Peptide for Injection 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Compound Bone Peptide for Injection Players 麻豆原创 Share by Revenue
2.7.3 Global Compound Bone Peptide for Injection 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Compound Bone Peptide for Injection Retrospective 麻豆原创 Scenario by Region
3.1 Global Compound Bone Peptide for Injection 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Compound Bone Peptide for Injection Global Compound Bone Peptide for Injection Sales by Region: 2018-2029
3.2.1 Global Compound Bone Peptide for Injection Sales by Region: 2018-2023
3.2.2 Global Compound Bone Peptide for Injection Sales by Region: 2024-2029
3.3 Global Compound Bone Peptide for Injection Global Compound Bone Peptide for Injection Revenue by Region: 2018-2029
3.3.1 Global Compound Bone Peptide for Injection Revenue by Region: 2018-2023
3.3.2 Global Compound Bone Peptide for Injection Revenue by Region: 2024-2029
3.4 North America Compound Bone Peptide for Injection 麻豆原创 Facts & Figures by Country
3.4.1 North America Compound Bone Peptide for Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Compound Bone Peptide for Injection Sales by Country (2018-2029)
3.4.3 North America Compound Bone Peptide for Injection Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Compound Bone Peptide for Injection 麻豆原创 Facts & Figures by Country
3.5.1 Europe Compound Bone Peptide for Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Compound Bone Peptide for Injection Sales by Country (2018-2029)
3.5.3 Europe Compound Bone Peptide for Injection Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Compound Bone Peptide for Injection 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Compound Bone Peptide for Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Compound Bone Peptide for Injection Sales by Country (2018-2029)
3.6.3 Asia Pacific Compound Bone Peptide for Injection Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Compound Bone Peptide for Injection 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Compound Bone Peptide for Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Compound Bone Peptide for Injection Sales by Country (2018-2029)
3.7.3 Latin America Compound Bone Peptide for Injection Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Compound Bone Peptide for Injection 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Compound Bone Peptide for Injection 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Compound Bone Peptide for Injection Sales by Country (2018-2029)
3.8.3 Middle East and Africa Compound Bone Peptide for Injection Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Compound Bone Peptide for Injection Sales by Type (2018-2029)
4.1.1 Global Compound Bone Peptide for Injection Sales by Type (2018-2023)
4.1.2 Global Compound Bone Peptide for Injection Sales by Type (2024-2029)
4.1.3 Global Compound Bone Peptide for Injection Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Compound Bone Peptide for Injection Revenue by Type (2018-2029)
4.2.1 Global Compound Bone Peptide for Injection Revenue by Type (2018-2023)
4.2.2 Global Compound Bone Peptide for Injection Revenue by Type (2024-2029)
4.2.3 Global Compound Bone Peptide for Injection Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Compound Bone Peptide for Injection Price by Type (2018-2029)
5 Segment by Application
5.1 Global Compound Bone Peptide for Injection Sales by Application (2018-2029)
5.1.1 Global Compound Bone Peptide for Injection Sales by Application (2018-2023)
5.1.2 Global Compound Bone Peptide for Injection Sales by Application (2024-2029)
5.1.3 Global Compound Bone Peptide for Injection Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Compound Bone Peptide for Injection Revenue by Application (2018-2029)
5.2.1 Global Compound Bone Peptide for Injection Revenue by Application (2018-2023)
5.2.2 Global Compound Bone Peptide for Injection Revenue by Application (2024-2029)
5.2.3 Global Compound Bone Peptide for Injection Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Compound Bone Peptide for Injection Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Jiangshi Pharma
6.1.1 Jiangshi Pharma Corporation Information
6.1.2 Jiangshi Pharma Description and Business Overview
6.1.3 Jiangshi Pharma Compound Bone Peptide for Injection Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Jiangshi Pharma Compound Bone Peptide for Injection Product Portfolio
6.1.5 Jiangshi Pharma Recent Developments/Updates
6.2 Zhitong Biopharma
6.2.1 Zhitong Biopharma Corporation Information
6.2.2 Zhitong Biopharma Description and Business Overview
6.2.3 Zhitong Biopharma Compound Bone Peptide for Injection Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Zhitong Biopharma Compound Bone Peptide for Injection Product Portfolio
6.2.5 Zhitong Biopharma Recent Developments/Updates
6.3 Xinbai Pharmaceutical
6.3.1 Xinbai Pharmaceutical Corporation Information
6.3.2 Xinbai Pharmaceutical Description and Business Overview
6.3.3 Xinbai Pharmaceutical Compound Bone Peptide for Injection Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Xinbai Pharmaceutical Compound Bone Peptide for Injection Product Portfolio
6.3.5 Xinbai Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Compound Bone Peptide for Injection Industry Chain Analysis
7.2 Compound Bone Peptide for Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Compound Bone Peptide for Injection Production Mode & Process
7.4 Compound Bone Peptide for Injection Sales and 麻豆原创ing
7.4.1 Compound Bone Peptide for Injection Sales Channels
7.4.2 Compound Bone Peptide for Injection Distributors
7.5 Compound Bone Peptide for Injection Customers
8 Compound Bone Peptide for Injection 麻豆原创 Dynamics
8.1 Compound Bone Peptide for Injection Industry Trends
8.2 Compound Bone Peptide for Injection 麻豆原创 Drivers
8.3 Compound Bone Peptide for Injection 麻豆原创 Challenges
8.4 Compound Bone Peptide for Injection 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Jiangshi Pharma
Zhitong Biopharma
Xinbai Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.